Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2026, declared Interim Dividend of Rs. 4 per equity share.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.5 pts more than Nifty Smallcap 250 and 10.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caplin Point Laboratories declared an interim dividend of Rs. 4 per equity share (200% on face value of Rs. 2) for FY 2025-26. The record date is May 30, 2026 for determining shareholder eligibility. For the full year FY26, consolidated revenue stood at Rs. 2,187 Crores (up 12.9% YoY), with PAT of Rs. 650 Crores (up 20.1% YoY). US market revenue grew 28.7% to Rs. 471 Crores. The company reported strong free cash reserves of Rs. 1,471 Crores and liquid assets of Rs. 2,726 Crores. Standalone PAT was Rs. 397 Crores. Auditors issued unmodified opinion on both standalone and consolidated financial statements.
The dividend represents a payout of approximately Rs. 30.4 Crores, which is well-supported by the company's strong cash position and profitability growth. The 20% YoY PAT growth signals healthy operational performance, particularly in the US market segment.